BioTime

Updated on Sep 25, 2024

Edit

Comment

Type Public Founded 1990		Website www.biotimeinc.com

Traded as NYSE MKT: BTX TASE: BTX Industry Biotechnology, regenerative medicine Key people Michael West, PhD (CEO) Angus Russell (Director; former CEO of Shire Plc) Stock price BTX (NYSEMKT) US$ 3.35 +0.12 (+3.72%)1 Mar, 4:00 PM GMT-5 - Disclaimer Headquarters Alameda, California, United States Profiles LinkedIn Twitter Facebook YouTube Google+

Update with biotime inc nyse mkt btx stock news now

BioTime, Inc. is a clinical-stage biotechnology company in the field of regenerative medicine headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange Market Exchange, ticker symbol BTX. BioTime focuses primarily on two areas: stem cell technology and products for use in regenerative medicine, focusing on areas such as oncology, orthopedics, blood diseases, and blood plasma volume expanders for use in surgery and treatment of traumatic injuries.

BioTime’s products currently on the market include Hextend, a blood plasma volume expander which is manufactured and distributed by Hospira (NYSE: HSP) and research reagents. Hospira was acquired by Pfizer in February 2015.

The company is in a pivitol clinical trial for age-related macular degeneration (AMD). On November 3, 2014 BioTime's subsidiary Cell Cure Neurosciences received FDA authorization to initiate a phase I/IIa trial of OpRegen, an embryonic stem cell-derived treatment for the dry-AMD.

8 december 2009 biotime inc nyse euronext opening bell

History

BioTime was founded in 1990 in Berkeley, California. The company initially focused on developing processes to cool living bodies, and related projects.

In 2007, the company appointed Michael D. West, Ph.D, as chief executive officer. West had been CSO and CEO of Advanced Cell Technology (and prior to that had founded Geron (NASDAQ: GERN), for which he secured venture capital investment from Kleiner Perkins Caufield & Byers and Venrock.

Also in 2009, BioTime secured $4.72 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to expand its "ACTCellerate" program, which it had acquired the previous year from Advanced Cell Technology for $250,000 plus royalties.

In October 2010, BioTime entered a license agreement with Teva (NYSE: TEVA) to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.5 million in funding from Israel's Office of the Chief Scientist.

In 2013, BioTime acquired the stem-cell assets of Geron Corporation, with the aim of restarting its embryonic stem cell-based clinical trial for spinal cord injury.

Subsidiaries

BioTime has a number of subsidiaries, including:

Asterias Biotherapeutics, which is re-initiating Geron's stem cell trial for spinal cord injury using the stem cell assets acquired from Geron in 2013. The CEO of this subsidiary is Pedro Lichtinger, former CEO of Optimer Pharmaceuticals, which along with Trius Therapeutics was acquired by Cubist Pharmaceuticals for $1.6 billion in July 2013. Asterias Biotherapeutics stock is traded on the New York Stock Exchange market exchange (NYSE MKT: AST).

Cell Cure Neurosciences. Based in Israel, Cell Cure Neurosciences is developing stem cell-based therapies for the treatment of retinal and neural degenerative diseases. In November 2014, the company received FDA clearance to start a 15-patient Phase 1/2a human clinical trial using human embryonic stem cell-derived retinal pigment epithelial cells to treat age-related macular degeneration (AMD).

LifeMap Solutions. In partnership with the Icahn School of Medicine at Mount Sinai, LifeMap solutions is developing and launching (mHealth) mobile apps. LifeMap Solutions and the Icahn School were one of the first five groups designated by Apple Inc to develop an app for Apple’s ResearchKit for iPhone, announced by Apple on March 9, 2015.

OncoCyte, which is developing products for the diagnosis and treatment of cancer.

OrthoCyte, which is developing cellular therapies designed to reverse spinal damage.

ESI BIO, which provides stem cell tools to the research community. ESI BIO was formerly known as ES Cell International, which BioTime acquired in April 2010. Established in Singapore in 2010, ES Cell International was the first group to make embryonic stem cell lines suitable for clinical trials available to researchers.

Board of Directors

BioTime’s Board of Directors includes:

Neal Bradsher. A chartered financial analyst (CFA), Bradsher is founder and president of Broadwood Capital. He was a board member of Questcor Pharmaceuticals until it was acquired by acquired by Mallinckrodt Pharmaceutics for $5.6 Billion in August 2014.

Stephen C. Farrell, CEO of Convey Health Solutions, and a former director of chairman of the audit committee of Questcor Pharmaceuticals, which was acquired by Mallinckrodt Pharmaceutics for $5.6 Billion in August 2014. Farrell formerly served as president of PolyMedica Corp., until it was acquired for $1.5 Billion in 2007 by Medco Health Solutions, the largest pharmacy benefit manager in the U.S.

Alfred Kingsley, chairman of the board. He is general partner of Greenway Partners LP and was formerly a senior advisor to billionaire investor Carl Icahn from 1968 to 1992.

Michael H. Mulroy, a business consultant. He formerly served as executive vice president of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals in August 2014. Mulroy held a variety of positions at Questcor including General Counsel and Chief Financial Officer.

Angus Russell, the retired Chief Executive Officer of Shire plc, a multinational specialty biopharmaceutical manufacturing company

Michael D. West, BioTime’s CEO

References

BioTime Wikipedia

(Text) CC BY-SA